The study is an important test of whether the drug, called Trodelvy, can live up to expectations set by Gilead's $21 billion deal to acquire it.
News Ticker
- [ March 20, 2023 ] New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA) News
- [ March 20, 2023 ] Applied Biomechanics Researcher, Apple Design Team – Apple – Cupertino, CA San Francisco Biotech Jobs
- [ March 19, 2023 ] QC Scientist II – Thermo Fisher Scientific – San Francisco, CA San Francisco Biotech Jobs
- [ March 18, 2023 ] Quality Scientist 4, Microbiology – Johnson & Johnson – Redwood City, CA San Francisco Biotech Jobs
- [ March 18, 2023 ] Sr. Manager, Global Market Development, Genetic Sciences – Thermo Fisher Scientific – Sunnyvale, CA San Francisco Biotech Jobs
Copyright © 2022 Biotech Networks, LLC
